Drug Profile
Research programme: Parkinsons disease therapeutics - Forma Therapeutics
Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator FORMA Therapeutics
- Developer FORMA Therapeutics; Medical Research Council; University of Liverpool
- Class Antiparkinsonians
- Mechanism of Action Deubiquitinating enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 28 Mar 2021 No recent reports of development identified for research development in Parkinson's-disease in USA